Claims

1. Use of a K_{ATP} channel opener or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing hyperghrelinemia or increasing a lean body mass or lean body mass/fat mass ratio in a subject having Prader-Willi Syndrome (PWS) or Smith-Magenis syndrome (SMS),

wherein the medicament comprising an effective amount of the K_{ATP} channel opener or the pharmaceutically acceptable salt thereof is to be administered to the subject for at least 10 weeks,

wherein the subject is not administered human growth hormone, and

wherein the K_{ATP} channel opener is diazoxide.

2. The use of claim 1, wherein the medicament is for reducing hyperghrelinemia in the subject having Prader-Willi Syndrome (PWS) or Smith-Magenis syndrome (SMS).

3. The use of claim 1, wherein the medicament is for increasing the lean body mass or lean body mass/fat mass ratio in the subject having Prader-Willi Syndrome (PWS) or Smith-Magenis syndrome (SMS), wherein the lean body mass or lean body mass/fat ratio in the subject having been administered the medicament for at least 10 weeks is increased by at least 2%.

4. The use of claim 3, wherein the lean body mass or lean body mass/fat ratio in the subject having been administered the medicament for at least 10 weeks is increased by at least 3%.

5. The use of claim 3 or 4, wherein the lean body mass or lean body mass/fat ratio in the subject having been administered the medicament for at least 10 weeks is increased by at least 4%.

6. The use of any one of claims 3-5, wherein the lean body mass or lean body mass/fat ratio in the subject having been administered the medicament for at least 10 weeks is increased by at least 5%.

7. The use of any one of claims 3-6, wherein hyperphagia of the subject having been administered the medicament for at least 10 weeks is reduced by at least 10%.

8. The use of any one of claims 3-7, wherein hyperphagia of the subject having been administered the medicament for at least 10 weeks is reduced by at least 20%.

9. The use of any one of claims 3-8, wherein hyperphagia of the subject having been administered the medicament for at least 10 weeks is reduced by at least 30%.

10. The use of any one of claims 3-9, wherein circulating concentration of IGF-1 in the subject having been administered the medicament for at least 10 weeks, is not increased.

11. The use of any one of claims 1-10, wherein the medicament comprises the K_{ATP} channel opener and the K_{ATP} channel opener is diazoxide.

12. The use of any one of claims 1-10, wherein the medicament comprises the pharmaceutically acceptable salt and the pharmaceutically acceptable salt is diazoxide choline.

13. The use of any one of claims 1-12, wherein the medicament is to be administered once per day.

14. The use of any one of claims 1-12, wherein the medicament is to be administered twice per day.

15. The use of any one of claims 1-14, wherein the medicament is to be administered for 1 or more years.

16. The use of any one of claims 1-15, wherein the medicament is to be administered orally.

17. The use of any one of claims 1-16, wherein the medicament further comprises at least one other active ingredient.

18. The use of any one of claims 1-17, wherein the medicament comprises at least one excipient that affects release of the K_{ATP} channel opener or the pharmaceutically acceptable salt thereof.

19. The use of any one of claims 1-17, wherein the medicament comprises at least one excipient that delays release of the K_{ATP} channel opener or the pharmaceutically acceptable salt thereof.

20. The use of any one of claims 1-19, wherein the subject is an adult.